The Quipazine Puzzle: Tiny Dose, Giant Psychedelic Question
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
The Quipazine Puzzle: Tiny Dose, Giant Psychedelic Question
-
ナレーター：
-
著者：
A single bracketed word - "[sic]" - appeared next to a reported dose of 0.5 mg, implying someone claimed a mescaline-like effect from less than a grain of salt. Quipazine has been studied since 1966, produced LSD-like substitution in animals, and provoked projectile vomiting in primates; so what exactly does it do in the human brain?
In this episode, we trace quipazine’s scientific trail from 1966 through rodent and primate studies, the shifting labels from antidepressant to psychedelic candidate, and the locked doctoral thesis that may hold part of the answer - can one molecule explain both psychedelic and emetic effects at similar doses?
Person: researchers (unnamed) who reported 0.5 mg dose marked "[sic]"
Date: 1966 (first appearance in literature)
Event: 1977 animal studies documenting psychedelic-like behaviors
Topic: serotonin 2-A receptor activation (head-twitch response, ketanserin blockade)
Status: doctoral thesis under embargo until 2030
- Reported dose printed next to the notation "[sic]": 0.5 mg
- First appearance of quipazine in scientific literature: 1966
- By 1971 quipazine described as an antidepressant-like agent
- 1977 animal studies showed head-twitch response indicative of serotonin 2-A activation
- Primate studies produced LSD-like behaviors plus projectile vomiting, linking psychedelic and emetic effects
To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.
© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません